naldemedine (Rx)

Brand and Other Names:Symproic
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet: Schedule II

  • 0.2mg

Opioid-induced Constipation

Indicated for opioid-induced constipation (OIC) in adults with chronic noncancer pain

0.2 mg PO qDay

Also see Administration

Dosage Modifications

Hepatic impairment

  • Mild or moderate (Child-Pugh A or B): No dose adjustment required
  • Severe (Child-Pugh C): Avoid use

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and naldemedine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Abdominal pain (8-11%)

            1-10%

            Diarrhea (7%)

            Nausea (4-6%)

            Vomiting (3%)

            Gastroenteritis (2-3%)

            Opioid withdrawal (1-3%)

            Frequency Not Defined

            Bronchospasm

            Rash

            Previous
            Next:

            Warnings

            Contraindications

            Known or suspected GI obstruction and patients at increased risk of recurrent obstruction, owing to the potential for GI perforation

            History of hypersensitivity to naldemedine; bronchospasm and rash reported

            Cautions

            Gastrointestinal perforation

            • GI perforation reported with use of another PAMORA in patients with conditions that may be associated with localized or diffuse reduction of structural integrity in the wall of the GI tract (eg, peptic ulcer disease, Ogilvie syndrome, diverticular disease, infiltrative GI tract malignancies, peritoneal metastases)
            • Consider risk with use in patients with these conditions or other conditions that might result in impaired integrity of the GI tract wall (eg, Crohn disease)
            • Monitor for severe, persistent, or worsening abdominal pain and discontinue naldemedine in patients who develop this symptom

            Opioid withdrawal

            • Clusters of symptoms consistent with opioid withdrawal include hyperhidrosis, chills, increased lacrimation, hot flush/flushing, pyrexia, sneezing, feeling cold, abdominal pain, diarrhea, nausea, and vomiting
            • Patients with blood-brain barrier disruption may be at increased risk for opioid withdrawal or reduced analgesia
            • Take into account the overall risk-benefit profile when prescribing naldemedine in such patients
            • Monitor for symptoms of opioid withdrawal

            Drug interaction overview

            • Substrate of CYP3A4 (major), P-gp, and UGT1A3 (minor)
            • Opioid antagonists: Avoid use with another opioid antagonist
            • Strong CYP3A4 inducers: Avoid coadministration, owing to potential for decreased efficacy of naldemedine
            • Moderate or strong CYP3A4 inhibitors: Monitor for potential naldemedine adverse effects, owing to increased plasma concentrations
            • P-gp inhibitors: Monitor for potential naldemedine adverse effects, owing to increased plasma concentrations
            Previous
            Next:

            Pregnancy

            Pregnancy

            Fetal/neonatal clinical considerations

            • Naldemedine crosses the placenta and may precipitate opioid withdrawal in a fetus or newborn, owing to the immature fetal blood-brain barrier
            • There are no available data with naldemedine in pregnant women to inform a drug-associated risk of major birth defects and miscarriage

            Lactation

            Unknown if distributed in human breast milk

            Naldemedine was present in the milk of rats

            Because of the potential for serious adverse reactions, including opioid withdrawal in breastfed infants, a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother

            If drug is discontinued in order to minimize drug exposure to a breastfed infant, advise women that breastfeeding may be resumed 3 days after the final dose

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Opioid antagonist with binding affinities for mu-, delta-, and kappa-opioid receptors

            Functions as a peripherally acting mu-opioid receptor antagonist (PAMORA) in tissues such as the GI tract, thereby decreasing the constipating effects of opioids

            Derivative of naltrexone to which a side chain has been added that increases the molecular weight and the polar surface area, thereby reducing its ability to cross the blood-brain barrier

            Absorption

            Peak plasma concentrations: 45 minutes (fasting); 2.5 hr (high-fat meal)

            A high-fat meal decreased the rate, but not the extent of absorption

            Distribution

            Protein bound: 93-94%

            Vd: 155 L

            Metabolism

            Primarily metabolized by CYP3A4 to nor-naldemedine, with minor contribution from UGT1A3 to form naldemedine 3-G

            Nor-naldemedine and naldemedine 3-G have been shown to have antagonistic activity for opioid receptors, with less potent effect than naldemedine

            Naldemedine also undergoes cleavage in the GI tract to form benzamidine and naldemedine carboxylic acid

            Elimination

            Half-life: 11 hr

            Excretion: 57% urine; 35% feces

            Previous
            Next:

            Administration

            Oral Administration

            May take with or without food

            Alteration of analgesic dosing regimen before initiating naldemedine is not required

            Patients receiving opioids for <4 weeks may be less responsive to naldemedine

            Discontinue naldemedine if treatment with opioids is also discontinued

            Storage

            Store in light-resistant container at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F)

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous